Kaya, Ismail SeckinAksoy, SecilMutlu, MelisTekin, CaglaTaskapilioglu, Mevlut OzgurTunca, BerrinCivan, Muhammet NafiOcak, Pinar EserKocaeli, HasanBekar, AhmetEgeli, UnalCecener, GulsahTolunay, Sahsine2024-06-122024-06-122021-01-011019-5149https://doi.org/10.5137/1019-5149.JTN.32057-20.3https://hdl.handle.net/11452/42079AIM: To determine the Wnt and SHH subtypes at the molecular level, and to compare them clinically by examining the changes in CTNNB1, AXIN, PTCH1, SMO, SUFU, and GLI1 mRNA expression in the medulloblastoma of a Turkish population determined according to patient selection criteria. In this context, the clinical distinction between Wnt and SHH groups are realized by considering the age, gender, survival time, location of the lesion, and radiological features of the patients.MATERIAL and METHODS: Molecular separation was performed by RT-PCR analysis of CTNNB1, AXIN, PTCH1, SMO, SUFU, and GLI1 mRNA expression changes.RESULTS: About 17.8% and 22.2% of the cases were included in the Wnt and the SHH group, respectively. When comparing group differences based on clinical and molecular data, 72.7% and 66.6% of matches were observed in the Wnt and the SHH group, respectively.CONCLUSION: It has been revealed that molecular analysis and grouping of patients with medulloblastoma can provide support for clinically determined subgroups.eninfo:eu-repo/semantics/closedAccessExpressionGeneMedulloblastomaWntShhMolecular diagnosisScience & technologyLife sciences & biomedicineClinical neurologySurgeryNeurosciences & neurologySurgeryArticle00067280260001155456531410.5137/1019-5149.JTN.32057-20.3